Company: PACB
Filing Date: 2025-01-30
Form Type: 8-K
Source: 0001299130-25-000015
Chunk: 0

Company: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Filing Date: 2025-01-30
Form: 8-K
Item: Item 5.02
Chunk 0
---
ITEM 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.

On January 24, 2025, the Board of Directors (the “ Board”) of Pacific Biosciences of California, Inc. (the “ Company”), upon the recommendation of its Corporate Governance and Nominating Committee, appointed Christopher M. Smith to serve as a Class III director effective January 30, 2025, with an initial term expiring at the Company’s 2025 annual meeting of stockholders. The Board did not appoint Mr. Smith to any committee at this time.

There are no arrangements or understandings between Mr. Smith, on the one hand, and the Company or any other persons, on the other hand, pursuant to which Mr. Smith was selected as a director. There are no related party transactions between the Company and Mr. Smith (or any of his immediate family members) requiring disclosure under Item 404(a) of Regulation S-K. Mr. Smith does not have any family relationships with any of the Company’s directors or executive officers. Mr. Smith will participate in the Company’s non-employee director compensation policy, as described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 29, 2024. In addition, the Company will enter into its standard form of indemnification agreement with Mr. Smith.

On January 29, 2025, David Meline, a member of the Board, notified the Company of his resignation from the Board, effective January 30, 2025. The Company is not aware of any disagreement between Mr. Meline and the Company on any matter relating to the Company’s operations, policies or practices that resulted in Mr. Meline’s resignation